The Archer® FusionPlex Lung panel is a targeted next-generation sequencing (NGS) test to detect EGFR vIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFR, NRG1, NTRK, RET, and ROS1 fusions and select point mutations in 14 key gene targets associated with lung cancer. The panel is powered by Archer’s proprietary Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing test, even without prior knowledge of fusion partners or breakpoints.
Key Features
Key fusion detection

Excellent small panel for focused interrogation of oncogenic fusion targets.

Detect splice variants and relevant mutations

Captures EGFR vIII and MET exon 14 skipping events, as well as prominent mutations in ALK, BRAF, EGFR, KRAS, RET, and ROS1.

Sample versatility

Wide sample type compatibility, including FFPE.

Streamlined, lyophilized workflow

Minimize hands-on time and replication error.

Specifications and Performance


Gene Targets

> 10ng

Input Nucleic Acid Required*

> 97%

Unique Molecular On-Target %

2.5 hours

Hands-on Time

9 hours

Total Time

Illumina and
Ion Torrent™


Fresh Frozen or FFPE

Sample Types

*Input recommendations for FFPE samples vary depending on Archer PreSeq® RNA QC score; 50ng input recommended in absence of PreSeq screening

Gene Targets


Fusion, splicing or exon-skipping

NeeD to Modify Your Panel?

Add any of our wet lab-validated designs to this panel with Archer Assay Designer to build an assay that fits your exact requirements.

  • Find Your Fit

This website stores cookies on your computer. These cookies are used to improve your website and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy.

We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.